{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:32:59Z","timestamp":1793712779674,"version":"4.6.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["D43CA260658"],"award-info":[{"award-number":["D43CA260658"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["D43CA260658"],"award-info":[{"award-number":["D43CA260658"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["D43CA260658"],"award-info":[{"award-number":["D43CA260658"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["D43CA260658"],"award-info":[{"award-number":["D43CA260658"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA221205"],"award-info":[{"award-number":["U54CA221205"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW009575"],"award-info":[{"award-number":["D43TW009575"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Cervical cancer is one of the most frequently diagnosed cancers and a leading cause of cancer-related deaths in women in low- and middle-income countries (LMICs), accounting for nearly 85% of the global cervical cancer burden. High-risk human papillomavirus (hrHPV) infection is the main cause of cervical cancer. Easy-to-use, rapid, scalable, high-throughput, and cost-effective HPV tests are urgently needed for low-resource settings. Atila Biosystems\u2019 clinically validated ScreenFire HPV Risk Stratification (RS) assay identifies 13 hrHPV in 4 groups based on their oncogenic risk (i.e., HPV16, HPV18\/45, HPV31\/33\/35\/52\/58, and HPV51\/59\/39\/56\/68). While the current standard format is subject to laboratory contamination Atila has developed an innovative, contamination-preventive Zebra BioDome format. Recently we published the analytical performance of ScreenFire RS Zebra BioDome on the BioRad CFX-96 real-time PCR instrument. This current study evaluated its analytical performance on three additional qPCR platforms: Atila Portable iAMP-PS96, Atila Powergene9600 Plus, and Thermo Fisher Quantstudio-7.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We tested 173 DNA samples from Nigerian women with cervical cancer. These samples were tested simultaneously using the ScreenFire HPV Zebra BioDome assay (M5FHPV-96) on four different real-time PCR machines (Atila portable iAMP-PS96, Atila Powergene9600 Plus, Thermo Fisher QuantStudio-7, and BioRad CFX-96). We used overall agreement rate and unweighted kappa values to compare different platforms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The overall agreement for detection of hrHPV using Atila portable iAMP-PS96 was 96.5% with kappa value 0.95 (95% confidence interval: 0.91\u20130.99) compared to Thermo Fisher QuantStudio-7, and 97.1% with kappa value 0.96 (95% confidence interval: 0.92\u20130.99) compared to BioRad CFX-96. For genotype HPV16 and risk stratification (RS) genotype groups (HPV18\/45, HPV31\/33\/35\/52\/58, and HPV51\/59\/39\/56\/68) agreement rates were all &gt;\u200998.3%. For Atila Powergene9600 Plus the overall agreement was 98.8% with a kappa value of 0.98 (95% confidence interval: 0.96\u20131.0) compared to Thermo Fisher QuantStudio-7, and 96.5% with a kappa value of 0.96 (95% confidence interval: 0.94\u20130.99) compared to BioRad CFX-96. The agreements for the HPV16 and RS genotype groups (HPV18\/45, HPV31\/33\/35\/52\/58, and HPV39\/51\/56\/59\/68) were at least 98.3%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The novel ScreenFire HPV Zebra BioDome format produced highly concordant hrHPV positivity and RS genotype results on all four qPCR platforms. The data suggests that this innovative technology has the potential to improve HPV testing uptake in low-resource settings without further investment in purchasing new equipment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13027-025-00651-5","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:14:01Z","timestamp":1745986441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Analytical performance of the ScreenFire HPV RS Zebra BioDome assay on four different qPCR platforms"],"prefix":"10.1186","volume":"20","author":[{"given":"Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godwin","family":"Imade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alani S.","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Anorlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Adewole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran O.","family":"Morhason-Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoudou","family":"Maiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demirkan B.","family":"Gursel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiene S.","family":"Sagay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folasade T.","family":"Ogunsola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"3","key":"651_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"651_CR2","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjos\u00e9 S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191\u2013203.","journal-title":"Lancet Glob Health"},{"key":"651_CR3","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health. 2016;4:e609\u201316.","journal-title":"Lancet Global Health"},{"key":"651_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/cncr.30667","volume":"123","author":"W Small Jr","year":"2017","unstructured":"Small W Jr., Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: A global health crisis. Cancer. 2017;123:2404\u201312.","journal-title":"Cancer"},{"key":"651_CR5","unstructured":"World Health organization. New recommendations for screening and treatment to prevent cervical cancer: https:\/\/www.who.int\/news\/item\/06-07-2021-new-recommendations-for-screening-and-treatment-to-prevent-cervical-cancer (Last Time Accessed, June 2024)."},{"issue":"3","key":"651_CR6","doi-asserted-by":"publisher","first-page":"e25474","DOI":"10.1016\/j.heliyon.2024.e25474","volume":"10","author":"JD Siqueira","year":"2024","unstructured":"Siqueira JD, Alves BM, Castelo Branco ABC, Duque KCD, Bustamante-Teixeira MT, Soares EA, Levi JE, Azevedo E, Silva G, Soares MA. Comparison of four different human papillomavirus genotyping methods in cervical samples: addressing method-specific advantages and limitations. Heliyon. 2024;10(3):e25474.","journal-title":"Heliyon"},{"key":"651_CR7","doi-asserted-by":"publisher","unstructured":"Desai KT, Ajenifuja KO, Adepiti CA, Inturrisi F, Dagnall C, Hoffman AC, Egemen D, Gage JC, Wentzensen N, de Sanjose S, Schiffman M. Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource settings. J Clin Microbiol 2024 Dec 31:e0163924. https:\/\/doi.org\/10.1128\/jcm.01639-24. Epub ahead of print.","DOI":"10.1128\/jcm.01639-24"},{"key":"651_CR8","doi-asserted-by":"publisher","first-page":"RP91469","DOI":"10.7554\/eLife.91469","volume":"12","author":"S de Sanjos\u00e9","year":"2024","unstructured":"de Sanjos\u00e9 S, Perkins RB, Campos N, Inturrisi F, Egemen D, Befano B, Rodriguez AC, Jer\u00f3nimo J, Cheung LC, Desai K, Han P, Novetsky AP, Ukwuani A, Marcus J, Ahmed SR, Wentzensen N, Kalpathy-Cramer J, Schiffman M, PAVE Study Group. Design of the HPV-automated visual evaluation (PAVE) study: validating a novel cervical screening strategy. Elife. 2024;12:RP91469.","journal-title":"Elife"},{"issue":"7","key":"651_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ijc.34151","volume":"151","author":"KT Desai","year":"2022","unstructured":"Desai KT, Adepiti CA, Schiffman M, et al. Redesign of a rapid, Lowcost HPV typing assay to support risk-based cervical screening and management. Int J Cancer. 2022;151(7):1142\u20139.","journal-title":"Int J Cancer"},{"issue":"2","key":"651_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijc.34698","volume":"154","author":"F Inturrisi","year":"2024","unstructured":"Inturrisi F, de Sanjos\u00e9 S, Desai KT, Dagnall C, Egemen D, Befano B, et al. A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study. Int J Cancer. 2024;154(2):241\u201350.","journal-title":"Int J Cancer"},{"issue":"6","key":"651_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/ajcp\/aqad181","volume":"161","author":"J Hou","year":"2024","unstructured":"Hou J, Belinson JL, Du H, Li C, Zhang W, Zhang L, Zhang Y, Qu X, Wu R. AmpFire HPV and screenfire RS HPV validation trial. Am J Clin Pathol. 2024;161(6):535\u201342.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"651_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13027-024-00622-2","volume":"19","author":"J Wang","year":"2024","unstructured":"Wang J, Imade G, Akanmu AS, Musa J, Anorlu R, Zheng Y, Garcia-Bedoya O, Sanchez GI, Belinson J, Kim K, Maiga M, Gursel DB, Sagay AS, Ogunsola FT, Murphy RL, Hou L. Analytic performance of screenfire HPV RS assay zebra biodome format and its potential for large-scale population HPV screening. Infect Agents Cancer. 2024;19(1):59.","journal-title":"Infect Agents Cancer"},{"key":"651_CR13","doi-asserted-by":"crossref","unstructured":"Zhang W, Du H, Huang X, Wang C, Duan X, Liu Y, Shi B, Zhang W, Qu X, Wei L, Schiffman M, Belinson JL, Wu R. Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening. Infect Agent Cancer. 2020; 23;15:65.","DOI":"10.1186\/s13027-020-00328-1"},{"issue":"1","key":"651_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13027-023-00504-z","volume":"18","author":"S Moyo","year":"2023","unstructured":"Moyo S, Ramogola-Masire D, Moraka NO, Tawe L, Noubary F, Motsumi K, Manowe G, Zuze B, Radibe B, Hungwe FTT, Mohammed T, Maphorisa C, Shapiro R, Gaseitsiwe S, Luckett R. Comparison of the AmpFire multiplex HPV assay to the Xpert\u00ae HPV assay for detection of human papillomavirus and cervical disease in women with human immunodeficiency virus: a pragmatic performance evaluation. Infect Agent Cancer. 2023;18(1):29.","journal-title":"Infect Agent Cancer"},{"issue":"1","key":"651_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13027-024-00585-4","volume":"19","author":"C Mungo","year":"2024","unstructured":"Mungo C, Guliam A, Chinula L, Inturrisi F, Msowoya L, Mkochi T, Jawadu S, de Sanjos\u00e9 S, Schiffman M, Tang JH, Smith JS. Comparison of the screenfire and Xpert HPV assays for the detection of human papillomavirus and cervical precancer among women living with HIV in Malawi. Infect Agent Cancer. 2024;19(1):24.","journal-title":"Infect Agent Cancer"},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"834800","DOI":"10.3389\/fpubh.2022.834800","volume":"10","author":"J Musa","year":"2022","unstructured":"Musa J, Kim K, Zheng Y, Qu Y, Joyce BT, Wang J, Nannini DR, Gursel DB, Silas O, Abdulkareem FB, Imade G, Akanmu AS, Wei J-J, Kocherginsky M, Kim K-YA, Wehbe F, Achenbach CJ, Anorlu R, Simon MA, Sagay A, Ogunsola FT, Murphy RL, Hou L. Accelerated epigenetic age among women with invasive cervical cancer and HIV-Infection in Nigeria. Front Public Health. 2022;10:834800.","journal-title":"Front Public Health"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-025-00651-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-025-00651-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-025-00651-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:14:07Z","timestamp":1745986447000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-025-00651-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1186\/s13027-025-00651-5","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is covered under IRB approval at Northwestern University (STU00207051), Jos University (JUTH\/DCS\/ADM\/127\/XXVII\/630) and Lagos University (CMUL\/HREC\/01\/18\/327).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}